Advertisement
AstraZeneca recently confirmed that it would commit USD 2 billion towards expanding its manufacturing base in Maryland as part of its much larger USD 50 billion programme to strengthen research and production capabilities across the United States by 2030. The initiative, aligned with the former US administration's appeal for greater domestic drug manufacturing, spans upgrades to the company's biologics facility in Frederick and a new clinical supply site in Gaithersburg. The investment will support 2,600 jobs in total, including hundreds of highly specialised roles, and marks the fourth project under AstraZeneca's long-term expansion strategy.
AstraZeneca stated earlier this week that it would invest USD 2 billion to expand its presence in Maryland, building on a previously unveiled USD 50 billion plan aimed at significantly enhancing its manufacturing and research operations across the United States by 2030. This comes as global pharmaceutical companies continue to scale up US-based production following calls by the former President Donald Trump for drugmakers to reduce reliance on imported active ingredients and finished pharmaceuticals. Advertisement
The Anglo-Swedish company's Maryland commitment includes the expansion of its biologics manufacturing hub in Frederick and the development of a new, state-of-the-art clinical supply facility in Gaithersburg. These enhancements are intended to support next-generation biologics and enable the production of investigational medicines for clinical trials.
AstraZeneca described this USD 2 billion tranche as the fourth instalment of its wider investment drive, confirming that the initiative would support 2,600 roles across the two Maryland locations, including around 300 highly skilled jobs. This aligns with earlier efforts by the company to respond to Washington's push for domestic production while simultaneously pursuing a full New York Stock Exchange listing and renegotiating drug pricing terms to benefit millions of American patients.
The Frederick facility, which already manufactures biologics such as vaccines and advanced therapies used in oncology, respiratory medicine, autoimmune conditions and rare diseases, is expected to see its commercial output nearly double once the expansion is complete. The company said the development would create 200 new specialised roles and 900 construction jobs, enabling the site to manufacture rare disease medicines for the first time.
In Gaithersburg, the new clinical manufacturing unit-scheduled to become fully operational by 2029-will generate a further 100 positions, retain 400 existing roles, and support approximately 1,000 construction-related jobs. This move follows earlier announcements by AstraZeneca regarding new facilities dedicated to cell therapy manufacturing, reflecting a broader industry shift towards complex biologics and personalised treatments.
Source - Reuters
5th Jun, 2025
25th May, 2023
11th May, 2023
27th Apr, 2023
Advertisement
Facebook
Whatsapp
